Our Firm

Lewis Saul & Associates, P.C. was founded over 25 years ago with the purpose of establishing a public interest law firm dedicated to protecting the rights of citizens. We have represented thousands of individuals in the areas of product liability, personal injury, civil rights, and consumer law.

 Firm Highlights

Levaquin Tendon Problems - Are They Really a Rare Occurrence?

Lewis Saul & Associates is investigating multiple cases of tendon injury associated with the antibiotic, Levaquin. Levaquin is in the fluoroquinolone class of antibiotics and is commonly prescribed for sinus infections, bladder infections, prostatitis, diverticulitis, and other serious bacterial infections. Although the manufacturer reports that Levaquin-associated tendon injury is rare, the increasing amount of published case reports, as well as adverse events reported to the FDA, suggest otherwise. If you have had a tendon injury related to your use of Levaquin, please contact Lewis Saul & Associates for a free consultation. Read more about Levaquin and other fluoroquinolones...

Lewis Saul & Associates is Investigating Employee Pension Losses

In a developing trend, corporations are finding ways to "game the system" to get rid of pension obligations or to raid pension plans themselves. Though Congress has set up an insurance scheme to help protect retiree pension benefits, often there are insufficient funds to cover pension losses. Lewis Saul & Associates believes that corporations and/or their fiduciaries should be held accountable when employees lose their hard earned pension funds. If you have information about pension plan abuse or misconduct, or have lost pension funds yourself, please contact Lewis Saul & Associates for a free consultation with a pension lawyer. Information you have could be important to saving pension benefits for you and others. Read more about recovering employees’ lost pensions...

First Celebrex case filed in Maine by Lewis Saul & Associates

On November 4, 2005, Lewis Saul & Associates filed a complaint with the United States District Court, District of Maine alleging that Celebrex caused the death of a 40 year old South Portland man. The complaint alleges that Pfizer, the manufacturer of Celebrex, knew or should have known of Celebrex’s propensity to cause heart attack and strokes, but instead chose to aggressively market the drug as a safe and effective way to treat pain. The complaint alleges that Celebrex is neither safe nor effective.

The case was transferred to the United States District Court for the Northern District of California after the Judicial Panel for Multi-district Litigation ordered that all federally-filed Celebrex and Bextra cases be consolidated to this court for pre-trial litigation. Lewis Saul & Associates is working with members of the Plaintiff’s Steering Committee to advocate that this case be one of the first cases chosen for trial. Read more about Celebrex and Bextra Litigation...

Lewis Saul & Associates Negotiates Better Deal for Dexatrim Users

Lewis Saul & Associates recently completed negotiations with bankruptcy counsel for Delaco, the company that assumed all liability for problems associated with the over-the-counter weight loss remedy, Dexatrim. Under the renegotiated Reorganization Plan, Dexatrim users with similar injuries at similar ages will receive the same compensation as long as their claim is not statute barred in either the jurisdiction where they took Dexatrim or the jurisdiction where they filed their Dexatrim claim. Lewis Saul & Associates also drafted more favorable terms for the administration of Dexatrim claims under the proposed settlement.

In part due to the success of the negotiations, there were no objections to Delaco’s Reorganization Plan. The Bankruptcy Court confirmed the Plan on February 15, 2006 and it went effective on March 13, 2006. All drugs containing Phenylpropanolamine, or PPA, were taken off the market on November 6, 2000 after a study linked PPA to hemorrhagic strokes. Read more about PPA litigation...

First Vioxx case filed in New Hampshire by Lewis Saul & Associates

Working together with local counsel in New Hampshire, Lewis Saul & Associates filed the case of DiMauro v. Merck in the United Stated District Court for the District of New Hampshire. The case has been reported to be the first filed in New Hampshire. The complaint alleges that after Ms. DiMauro ingested 50 mg of Vioxx as prescribed, she suffered a heart attack at the age of 58. Prior to the heart attack, Ms. DiMauro was a healthy and active woman with no significant medical history.

The case was transferred to the United States District Court for the Southern District of Louisiana where all Vioxx cases have been consolidated for pre-trial proceedings. Read more about Vioxx litigation...